A Study of GQ1005 in Subjects With HER2-Expressing Advanced Solid Tumors

Summary

This is an open-label, phase I study to evaluate the safety, tolerability, pharmacokinetics and immunogenicity of GQ1005 and preliminary anti-tumor efficacy in HER2 expressing or mutated advanced malignant solid tumor subjects.

Timeline

Start

2022-11-23

Primary completion

2024-12-31

Completion

2025-07-30

Drugs

Indications